BW Offshore
Completion of BW Ideol transactions
Reference is made to stock exchange announcement made by BW Offshore Limited on 17 February 2021 regarding the investment in Ideol S.A. creating BW Ideol AS (the "Transaction").
After obtaining regulatory approval and following satisfaction of other conditions, BW Ideol AS today completed the share purchase agreement and acquired Ideol S.A. The agreed funds have been transferred to the selling shareholders of Ideol S.A. who have sold their shares for cash and BW Ideol AS will issue a total of 5,815,240 shares to the sellers who have elected to contribute their shares in Ideol S.A. for shares in BW Ideol AS, following registration of the share capital increase in the Norwegian Register of Business Enterprises.
Following the above-mentioned completion, BW Ideol holds 100% of the shares outstanding in Ideol S.A.
For further information, please contact:
Anders S. Platou, Head of Corporate Finance, +47 99 50 47 40
IR@bwoffshore.com or www.bwoffshore.com
About BW Offshore:
BW Offshore engineers innovative floating production solutions. The Company has a fleet of 15 FPSOs with potential and ambition to grow. By leveraging four decades of offshore operations and project execution, the Company creates tailored energy solutions for evolving markets world-wide. BW Offshore has around 2,000 employees and is publicly listed on the Oslo Stock Exchange.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Una Holmen, Manager IR, BW Offshore on 15 March at 20.00.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novo Nordisk A/S17.9.2025 23:05:02 CEST | Press release
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Biogen Inc.17.9.2025 22:30:05 CEST | Press release
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Atico Mining Corporation17.9.2025 22:30:00 CEST | Press release
Atico Signs the Investment Protection Agreement with Government of Ecuador for its La Plata Project
Frontline plc.17.9.2025 22:06:51 CEST | Press release
FRO – Filing of Half Yearly Report
VCI Global Limited17.9.2025 21:00:00 CEST | Press release
VCI Global Initiates Rescission and Cancellation of Shares from QuantGold Transaction, Tightening Capital Structure Following Reverse Split
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom